Neurocrine Biosciences (NBIX) Net Cash Flow (2010 - 2026)
Neurocrine Biosciences (NBIX) posted quarterly Net Cash Flow of $64.4 million for Q2 2026, down 7.6% year-over-year from $69.7 million in Q2 2025, and up 114.42% on a QoQ basis from -$446.5 million in Q1 2026.
Neurocrine Biosciences (NBIX) Net Cash Flow (2010 - 2026) Analysis & Trends
Neurocrine Biosciences has reported Net Cash Flow for 17 years, with the latest figure at $64.4 million in Q2 2026.
- Net Cash Flow for Q2 2026 came in at $64.4 million, down 7.6% year-over-year; the trailing twelve-month figure through Jun 2026 was $67.1 million (down 45.93% YoY), and the FY2025 annual result was $480.0 million, up 2751.93% from the prior year.
- Net Cash Flow grew to $64.4 million in Q2 2026, from -$446.5 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $372.8 million in Q4 2025 and troughed at -$446.5 million in Q1 2026.
- A 5-year average of -$227777.8 and a median of $50.4 million in 2022 frame the typical range for Net Cash Flow.
- The widest annual swing landed in 2025, when Net Cash Flow soared 421.93%; it then tumbled 1047.81% in 2026.
- A 5-year view of Net Cash Flow shows it stood at $52.0 million in 2022, then tumbled by 182.5% to -$42.9 million in 2023, then plunged by 169.93% to -$115.8 million in 2024, then soared by 421.93% to $372.8 million in 2025, then sank by 82.73% to $64.4 million in 2026.
- Per Business Quant data, the three most recent Net Cash Flow figures were $64.4 million in Q2 2026, -$446.5 million in Q1 2026, and $372.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn | -81.00 Mn |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn | -458.00 Mn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | -881.03 Mn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 523.50 Mn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | -912.40 Mn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 64.40 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 93.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | - |
| 10 | Alkermes | 8.12 Bn | 7.46 Bn | 397.90 Mn | 159.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 64.40 Mn |
| Jun 30, 2026 | 64.40 Mn |
| Mar 31, 2026 | -446.50 Mn |
| Mar 31, 2026 | -446.50 Mn |
| Dec 31, 2025 | 372.80 Mn |
| Dec 31, 2025 | 372.80 Mn |
| Sep 30, 2025 | 76.40 Mn |
| Sep 30, 2025 | 76.40 Mn |
| Jun 30, 2025 | 69.70 Mn |
| Jun 30, 2025 | 69.70 Mn |
| Mar 31, 2025 | -38.90 Mn |
| Mar 31, 2025 | -38.90 Mn |
| Dec 31, 2024 | -115.80 Mn |
| Dec 31, 2024 | -115.80 Mn |
| Sep 30, 2024 | 209.10 Mn |
| Sep 30, 2024 | 209.10 Mn |
| Jun 30, 2024 | -256.60 Mn |
| Jun 30, 2024 | -256.60 Mn |
| Mar 31, 2024 | 145.20 Mn |
| Mar 31, 2024 | 145.20 Mn |